Related Experiment Video

Updated: May 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy

Ali R Jazirehi1, Peter B Wenn, Mohsen Damavand

  • 1Department of Surgery, Division of Surgical Oncology, and the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles Los Angeles, CA, USA. ajazirehi@mednet.ucla.edu

American Journal of Cancer Research
|April 10, 2012
PubMed

Insights

Targeting the PI3K/AKT/mTOR pathway offers a promising strategy for melanoma treatment. Inhibiting this signaling module shows potential in reducing tumor growth and improving survival rates in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The PI3K/AKT/mTOR pathway regulates critical cellular processes like survival, growth, and metabolism.
  • Dysregulation of this pathway, particularly AKT, is prevalent in cancers, including melanoma, leading to apoptosis resistance.
  • AKT signaling interacts with other pathways (NF-κB, MAPK) promoting tumor development.

Purpose of the Study:

  • To review the role of the PI3K/AKT/mTOR pathway in melanoma.
  • To explore its cross-talk with other survival pathways.
  • To summarize targeted inhibition strategies for melanoma therapy.

Main Methods:

  • Literature review of PI3K/AKT/mTOR signaling in melanoma.
  • Analysis of cross-talk with other cellular pathways.
  • Summary of preclinical and clinical trial data on targeted inhibitors.

Main Results:

  • Aberrant AKT expression is found in ~60% of melanomas, conferring apoptosis resistance.
  • AKT pathway activation contributes to tumor development and progression via cross-talk with other signaling cascades.
  • Pharmacological inhibitors targeting this module have demonstrated efficacy in reducing tumor proliferation and survival.

Conclusions:

  • Targeted inhibition of the PI3K/AKT/mTOR pathway is a viable therapeutic strategy for melanoma.
  • Combination therapies involving these inhibitors show promise.
  • Further clinical investigation of these targeted agents is warranted.
Keywords:
AKTPI3KinasePTENapoptosismTORmelanomaresistancesignal transductiontargeted therapy

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...